Urolithin A Supplementation During Pulmonary Rehabilitation in Patients With COPD

Study acronym: SUPRA-COPD
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Bryan A. Ross
1 trial monitored
See all monitored trials
COPD
1,120 trials monitored
See 36 trials at risk
SUPRA-COPD is a multicenter triple-blind, parallel arm, placebo-controlled randomized controlled trial investigating the efficacy and safety of Urolithin A supplementation during pulmonary rehabilitation in patients with COPD. The goal of the SUPRA-COPD study is to investigate whether Urolithin A supplementation during pulmonary rehabilitation in patients with COPD improves exercise tolerance, along with several other clinically important outcomes, above and beyond pulmonary rehabilitation participation alone. Study participation will be approximately 14 weeks and involves in-person visits evaluating exercise tolerance before and after PR.
Trial Details
NCT Number NCT07871357
Lead Sponsor Bryan A. Ross
Collaborators: Canadian Institutes of Health Research (CIHR), Amazentis SA, McGill University Health Centre/Research Institute of the McGill University Health Centre, Jewish General Hospital (Montreal, Quebec, Canada), Ottawa Hospital Research Institute
Conditions
(from sponsor)		 Chronic Obstructive Pulmonary Disease (COPD)
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 198 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov